Articles tagged with Cancer Medication
Researchers at UC San Diego School of Medicine discovered a new way to treat cancer by manipulating macrophages, immune cells found in tumor tissues. IRE1α, a molecule regulating the unfolded protein response, was shown to boost PD-L1 levels on macrophages, allowing tumors to evade the immune system.
A recent study by SWOG Cancer Research Network found that black cancer patients are more likely to be enrolled in taxpayer-funded clinical trials compared to industry-sponsored trials. The study analyzed data from over 93,000 patients across 358 trials and found a significant disparity in representation.
Scientists at City of Hope and TGen found that circulating immune cell dynamics can inform how patients respond to immunotherapy. The study's findings highlight an important predator-prey relationship between immune cells and tumor response.
A large retrospective cohort study found that flu vaccination was associated with a small increased risk for subdeltoid bursitis. Researchers suggest education and training on proper injection technique could prevent this adverse event.
A new class of precision medicine targeting cancer's ability to repair its DNA has shown promising results, with half of patients experiencing tumor growth halt. The drug works by stopping cancers from repairing DNA damage and is particularly effective when combined with chemotherapy.
Researchers at the University of South Australia have developed a novel formulation of the prostate cancer drug abiraterone acetate, improving its effectiveness by 40%. The new oral formulation reduces side effects and allows for a smaller dose to be effective without fasting.
KinaRx aims to create more effective drugs using a novel platform that targets gene mutations driving cancer growth. The company has developed novel RET inhibitors with promising results in preclinical experiments.
Researchers have found that certain cancer therapeutics concentrate within cells' tiny functional compartments called organelles, known as condensates. This discovery could lead to a new toolset for drug development by tailoring chemicals to seek out and concentrate in specific droplets.
A 84-year-old woman with breast cancer and controlled hypertension developed a life-threatening arrhythmia after chloroquine treatment, resolving after discontinuation. The case highlights the risks of QT interval prolongation and torsade de pointes in patients treated with chloroquine for COVID-19.
A cancer drug called ruxolitinib was used to treat a COVID-19 patient with acute respiratory distress, resulting in clinical stabilization and rapid improvement in respiration and heart function. The treatment's success has led to the approval of a clinical trial to test its effect on additional COVID-19 patients.
A new study has discovered a direct link between mutations in the p53 tumor suppressor gene and the KRAS oncogene, driving the formation of pancreatic cancer. The research provides insight into the mechanism that regulates cell activity, offering potential therapeutic targets for future development.
A new study by American Cancer Society finds that cancer survivors experiencing higher medical and nonmedical financial hardships are more likely to visit the emergency department, receive less preventive care, and have worse self-rated health. The study highlights the growing healthcare costs and their impact on worsening health dispa...
Researchers developed a new test, PrOTYPE, to classify high-grade serous ovarian cancer into four molecular subtypes. This test allows clinicians to tailor treatments to individual patients' tumours with over 95% accuracy.
Researchers developed a new method, HT-DBP, to screen thousands of drugs in freshly collected human tumor cells, potentially leading to more accurate and personalized treatment. The technique indicates which drugs are most likely to be effective against specific cancers, improving physicians' ability to tailor treatment.
In a phase 2 trial, berzosertib, an ATR protein inhibitor, was found to significantly extend progression-free survival for patients with ovarian cancer compared to chemotherapy alone. The drug targets a protein crucial for cancer cell growth and division.
City of Hope scientists have developed two potent small molecules, CS1 and CS2, which inhibit the FTO protein and suppress tumor growth in various cancers. The compounds demonstrate significant anti-tumor effects and improved overall survival in mice with acute myeloid leukemia and breast cancer.
Ashion Analytics has been certified for the National Cancer Institute's MATCH program, offering a comprehensive genomic analysis of all possible cancer mutations in DNA and RNA. This allows for personalized treatment options and potentially life-changing outcomes.
The COVID-19 pandemic is worsening existing drug shortages in the US, particularly for cancer treatments and critical care medications. Experts recommend improved communication and sharing mechanisms among hospitals and healthcare providers to address these shortages.
Researchers create sugar-tagged drug compounds to target chemotherapy-resistant prostate cancer cells, exploiting the Warburg effect. The new compound shows improved efficiency in killing cancer cells compared to traditional chemotherapeutic drugs.
Researchers at Yale University have made a breakthrough in treating Rett Syndrome, a devastating genetic disorder affecting 1 in 10,000 girls. The experimental cancer drug JQ1 has been shown to extend the life of mice with Rett Syndrome by approximately 50%.
Researchers at NUI Galway have discovered a key role for CDC7 in cancer cell replication, providing new insights into developing novel treatments. The study found that blocking CDC7 could be an effective strategy for treating aggressive cancers like pancreatic and colon cancer.
Researchers have identified a new strategy to tackle cancer by inducing toxic autophagy in tumor cells, resulting in cell destruction. The antitumor drug ABTL0812 has been shown to manipulate dihydroceramides, a group of cellular lipids, causing stress and ultimately leading to cancer cell death.
Oncology pharmacy practitioners worldwide are struggling with limited and restricted PPE supply, making it difficult for them to provide high-quality cancer care. In a study, half of the surveyed countries reported impaired access to essential medications, including anti-infective agents and anticancer medications.
A new study found that cancer cells adapt by gobbling up fat molecules from their environment when they can't make their own, potentially rendering treatments ineffective. The research identified a new gene, LUR1, involved in lipid uptake and suggests targeting this process could lead to more effective cancer treatments.
Researchers have identified a variant in the genome associated with higher risk of prostate cancer in African American men. This variant is found in about 12% of men of African ancestry and increases their risk two-fold.
Researchers at Dartmouth Health have found that HPV vaccines effective in the US may not provide adequate protection for women in low- and middle-income countries due to differing prevalence of HPV strains. This has significant implications for cervical cancer prevention and treatment in these regions.
Researchers discovered that cancer cells generate a high number of errors when copying their DNA under treatment, fuelling resistance. Combining targeted therapy with DNA repair mechanism-targeting drugs may lead to more effective therapeutic strategies.
A new technology has been developed to rapidly create homogeneous antibody-drug conjugates (ADCs) that target specific sites on cancer cells. The USC team's approach offers improved efficiency and potential enhanced stability, effectiveness, and safety compared to current methods.
Researchers have identified key changes in a molecular pathway that plays critical roles in human development, blood pressure regulation, inflammation, and cell death. The findings provide a blueprint for drug development and shed light on how common medications interact with the target.
A review of 56 randomized clinical trials found that cognitive behavior therapy is superior to other psychotherapies in reducing inflammation and boosting the immune system. CBT was most effective in reducing pro-inflammatory cytokines, which are associated with chronic diseases such as heart disease, cancer, and Alzheimer's disease.
Basic research funding for cancer therapies reached $64 billion, with the NIH contributing $20 billion and other institutes providing the majority of the remaining funds. This funding enabled the development of innovative immunotherapies for cancer.
SYNB1891, an engineered E. coli Nissle strain producing cyclic di-AMP, demonstrates anti-tumor activity and generates immunological memory in preclinical models of cancer. The therapy is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors or lymphoma.
Researchers found that children with birth defects are more likely to develop certain types of cancer, including neuroblastoma and hepatoblastoma, and are diagnosed earlier in life. The study compared data from nearly 14,000 children with cancer to those with cancer and one or more birth defects.
Researchers identified key features of tumors that influence response to immune checkpoint inhibitor drugs in advanced kidney cancer. Unlike other types of cancer, high infiltration by CD8 T cells actually led to a worse outcome, contradicting previous observations.
Myeloma Drug Sensitivity Testing (My-DST) uses liquid biopsies to test drug effectiveness on patient samples. The approach shows promise in predicting real patient responses, and may guide drug development for multiple myeloma treatment.
A WPI-led research team has identified drugs that target triple-negative breast cancer tumors in mice without inducing toxic side effects. The targeted therapies use molecular recognition units to specifically target the tumors, reducing their sizes and eliminating them.
A transgenic mouse model of HLH has been found to be effective in treating severe COVID-19 patients by calming the 'cytokine storm', a common feature of children battling secondary HLH. Ruxolitinib showed promising results, with 90% of patients showing CT scan improvement within 14 days.
Researchers identified an enzyme, p38α kinase, as crucial for metastasis, which is the primary cause of cancer deaths. By blocking this enzyme using an inhibitor, they successfully reduced melanoma's spread to the lungs and prolonged survival time.
A phase III clinical trial has shown that immunotherapy drug 'avelumab' significantly improves survival in patients with the most common type of bladder cancer. Treatment with avelumab resulted in a 31% reduction in risk of death and extended median survival by over seven months.
Oncologists are calling for more time spent on education about palliative care and discussing 'bad news' with patients. Research shows cancer doctors have limited coaching in this area, which can impact patient preferences for treatment or palliative care.
Researchers found that cancer therapy can trigger the formation of large, aggressive cells with multiple chromosomes. A scientist is now developing a drug to prevent or treat these rogue cells, which can lead to cancer recurrence.
Researchers identified WWP1 mutations as a genetic driver of PTEN hamartoma tumor syndrome-associated cancer. The study found that WWP1 variants lead to abnormal activation of the enzyme inhibiting PTEN function and contributing to cancer development, suggesting a new therapeutic target.
Scientists develop method to preserve beneficial properties of polyphenols and flavonoids in cancer treatment, resulting in highly effective and low-toxicity therapies.
Researchers have discovered a new class of immunotherapy that targets myeloid immune cells and slows tumor growth by inhibiting the c-Rel molecule. The treatment showed promising results in both human cells and mouse models, shrinking tumors by up to 80% and reducing immune suppressor cells.
Olaparib, a PARP inhibitor, targets genetic mutations in advanced prostate cancer patients with BRCA1 and BRCA2. The FDA approved the drug for homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
Researchers discovered that lumefantrine, an FDA-approved anti-malarial drug, can inhibit the genetic element Fli-1 controlling resistance to radiation and chemotherapy in glioblastoma multiforme. Lumefantrine also suppresses tumor cell growth and inhibits key processes regulating cancer invasion and spread.
Recent studies have shown that Clioquinol exhibits anti-tumor activities in various cancer cell lines, inhibiting growth and inducing cytotoxicity. However, its clinical efficacy is limited due to poor absorption by tumor cells. Researchers are exploring novel combinations, delivery methods, and analogues of Clioquinol for improved can...
Researchers at the University of Southampton have discovered a way to convert an antagonist CD40 antibody into an agonist, which can stimulate the immune system and cure cancer more effectively. The study shows that this
The UCLA Jonsson Comprehensive Cancer Center has been awarded a $5.75 million grant to study the role of obesity in the development of pancreatic cancer. The research aims to understand how inflammation from obesity influences tumor formation and develop prevention strategies for high-risk individuals.
Scientists are conducting a randomized trial to assess the efficacy of ibrutinib, a blood cancer treatment, in reducing supplemental oxygen needs and shortening hospital stays for COVID-19 patients. The goal is to improve survival rates among those with breathing problems caused by the virus.
A new study by The Institute of Cancer Research reveals that delays in cancer surgery due to the Covid-19 pandemic could result in thousands of additional deaths. The modelling suggests that a three-month delay would lead to an additional 4,755 deaths and 92,214 years of life lost.
YIV-906, a first-in-class botanical drug candidate developed through NFCR funding, commences Phase IIB clinical trials for hepatitis B-associated liver cancer. The drug has demonstrated safety and promising efficacy in early-stage trials and may improve survival and quality of life for patients.
A newly identified biomarker could help scientists pinpoint which cancers are vulnerable to treatment with biguanides, a common class of medications used to control blood sugar in Type 2 diabetes. The biomarker is linked to the gene MYC and has been found to be regulated by microRNAs that target certain cancer cells.
Researchers developed TransPRECISE to combine molecular data, drug profiling, and cancer cell lines to understand tumor behavior. The tool accurately predicted potential therapeutic efficiency of drugs and identified key targets.
Researchers at the University of Texas Health Science Center at San Antonio identified key drivers of tumor plasticity, a phenomenon where cancer cells change their behavior to evade treatments. The study found that targeting these genetic signals could increase therapy effectiveness and potentially cure more cancers.
A new LAT1 inhibitor has been developed that can induce apoptosis in cancer cells without affecting brain amino acid homeostasis. The inhibitor was tested in vitro and found to be hemocompatible, making it a promising treatment option for various cancers.
Researchers discovered a new mechanism for regulating RAS enzyme activity that will inform therapeutic strategies for inhibiting mutated RAS proteins involved in cancer. The study found that close proximity on the cell membrane is required for one RAS protein to interact with other RAS proteins.
A new study by SWOG Cancer Research Network found that simple text reminders do not improve breast cancer hormone therapy adherence. The study enrolled 724 post-menopausal women and tested the effectiveness of brief, twice-weekly text messages reminding them to take their medication.
A new treatment combination of atezolizumab and bevacizumab has significantly improved survival for people with hepatocellular carcinoma, reducing mortality risk by 42% and increasing cancer response rates. The therapy is being reviewed for FDA approval under a Real-Time Oncology Review pilot program.
The EULAR 2020 study investigates the connection between breast cancer, anti-hormonal therapy, and rheumatoid arthritis. The results show that the risk of breast cancer in women with RA is lower than in women with healthy joints, and no association was found between anti-hormonal breast cancer prophylaxis and later RA.